COMMUNIQUÉ DE PRESSE publié le 29/02/2024 à 22:05, il y a 2 années 2 mois Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers Sonnet BioTherapeutics Holdings, Inc. announced the publication of clinical data on SON-1010, a tumor-targeted immunotherapeutic drug combining FHAB construct with IL-12 in Frontiers in Immunology, showing favorable safety and tolerability Clinical Data Sonnet BioTherapeutics SON-1010 Immunotherapeutic Drug FHAB Technology
COMMUNIQUÉ DE PRESSE publié le 14/02/2024 à 13:30, il y a 2 années 2 mois Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update Sonnet BioTherapeutics Holdings, Inc. successfully raised $4.55 million, published preclinical data on SON-1210, executed NJ NOLs agreement, Phase 1b SON-080 trial enrollment completed, financial results announced for quarter ended Dec 31, 2023 Financial Results Preclinical Data Public Offering Sonnet BioTherapeutics Holdings NJ NOLs
COMMUNIQUÉ DE PRESSE publié le 21/12/2023 à 14:00, il y a 2 années 4 mois Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy
COMMUNIQUÉ DE PRESSE publié le 14/12/2023 à 22:15, il y a 2 années 4 mois Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update
COMMUNIQUÉ DE PRESSE publié le 31/10/2023 à 12:30, il y a 2 années 6 mois Sonnet BioTherapeutics Provides Fiscal Year 2023 Business Overview
COMMUNIQUÉ DE PRESSE publié le 25/10/2023 à 13:30, il y a 2 années 6 mois Sonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public Offering
COMMUNIQUÉ DE PRESSE publié le 17/10/2023 à 14:00, il y a 2 années 6 mois Sonnet BioTherapeutics Announces Abstract Accepted for Presentation by a Key Opinion Leader at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting
COMMUNIQUÉ DE PRESSE publié le 20/09/2023 à 13:30, il y a 2 années 7 mois Sonnet BioTherapeutics Announces Results of Biodistribution Studies Demonstrating Solid Tumor Targeting Using the FHAB Technology
Publié le 07/05/2026 à 19:15, il y a 1 jour 2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Publié le 07/05/2026 à 19:15, il y a 1 jour Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Publié le 07/05/2026 à 19:06, il y a 1 jour Disclosure of Share Capital and Voting Rights as of April 30, 2026
Publié le 07/05/2026 à 19:06, il y a 1 jour Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Publié le 07/05/2026 à 19:00, il y a 1 jour ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Publié le 08/05/2026 à 15:55, il y a 3 heures 24 minutes Class 1 Nickel and Technologies Ltd. Announces Private Placement and Share for Debt Offering
Publié le 08/05/2026 à 15:00, il y a 4 heures 19 minutes Jaguar Health Regains Compliance with Nasdaq's Publicly Held Shares Requirement and Receives Additional Extension, Until May 18, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule
Publié le 08/05/2026 à 14:55, il y a 4 heures 24 minutes Nepra Foods Inc. to Present at the 16th Annual LD Micro Invitational
Publié le 08/05/2026 à 14:30, il y a 4 heures 49 minutes Unusual Machines Hosts Live Drone Ecosystem Demonstrations at XPONENTIAL 2026
Publié le 08/05/2026 à 14:00, il y a 5 heures 19 minutes BlackBerry Announces Renewal of Normal Course Issuer Bid Share Buyback Program
Publié le 08/05/2026 à 19:02, il y a 17 minutes Metall Zug – Annual General Meeting of Shareholders approves all proposals
Publié le 08/05/2026 à 17:54, il y a 1 heure 25 minutes Turkiye Garanti Bankasi A.S.: CMB Approval for Bond Issuance to Foreign Markets